Abstract The Committee of Clinical Practice Guidelines of the Korean Diabetes Association
(KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and …

Summary 415 million people live with diabetes worldwide, and an estimated 193 million
people have undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

Aims To review the evolution and advancement of GLP‐1 receptor agonist (GLP‐1RA)
therapy, through the lens of randomised controlled trials, from differentiating characteristics …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …

Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor
(GLP-1R) result in weight loss in overweight or obese patients with or without type 2 …

Insulin resistance in muscle and liver and-cell failure represent the core pathophysiologic
defects in type 2 diabetes. It now is recognized that the-cell failure occurs much earlier and …

Insulin is essential for type 1 and advanced type 2 diabetics to maintain blood glucose levels
and prolong lives. The traditional administration requires frequent subcutaneous insulin …

To achieve good metabolic control in diabetes and keep long term, a combination of
changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal …

This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic …